Doctors in the U.S. are refusing to prescribe a drug used to treat Crohn’s disease, saying the drug will not help patients with a condition in which the body can’t produce enough of the medication to fight the disease.
The drug, called Cialis, is available to some patients in the United Kingdom but has yet to be approved in the country, according to a statement from the University of Chicago Medical Center.
It was approved in 2015, and it is not known how many people have taken it.
Cialus is made from a drug called amitriptyline and can be given orally or IV.
It can be used to slow down the growth of certain types of Crohnís disease.
But the American Academy of Neurology (AAN) has said it has concerns about the safety of the drug and the risk of side effects, including the drug’s ability to reduce a patient’s ability for bowel movements.
The AAN says the drug can also be harmful to a patient with Crohn`s disease if taken too frequently.
AAN wrote in a statement that it is “disappointed” in the American Society of Clinical Oncology (ASCO) that the American Psychiatric Association has voted to keep Cials approval from being extended to the U, and that the AAN is urging other academic and medical societies to take a similar stance.
The American Academy’s position is “that there are significant safety concerns with the drug,” the statement said.
Doctors in other countries have also expressed concern about the drug.
A spokesperson for the UK’s National Health Service (NHS) told Reuters Health that the drugs approval “has not yet been accepted in the UK and is currently being reviewed by NHS.
It is currently undergoing clinical trials.”
The drug was approved to treat the condition in the US in 2016.
In a statement, the NHS said it “does not support” the “tremendous concern” expressed by the AANS.
The U.k. has already approved the drug for use to treat people with Crohns, the spokesperson added.
The statement comes amid growing calls in Europe for the United States to take up Cialicas approval.
The European Medicines Agency (EMA) has approved a drug to treat inflammatory bowel disease, and there are signs the U of T is preparing to approve another treatment for Crohn�s.
Last month, the U and the University College London announced they would collaborate on an experimental drug for the disease, known as TNF-alpha inhibitor xtamethonium.
In the U., there are also plans to expand use of Cialics approval.
